
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for RJF.MC and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RJF.MC and 80,000+ other tickers.
See exactly how RJF.MC's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RJF.MC and 80,000+ other tickers.
Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs, over-the-counter (OTC) products, medical devices, and cosmetics. The company's offerings are categorized into several key areas: advanced pharmaceutical technologies, which include antibiotics and injectable formulations; specialized healthcare solutions targeting dermatological, musculoskeletal (joint health and pain), women's health…
No recent news available.